Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 08 May 2025
At a glance
- Drugs Pacritinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Nov 2024 Planned End Date changed from 2 Nov 2024 to 22 Jul 2025.
- 18 Nov 2024 Planned primary completion date changed from 2 Nov 2024 to 22 Jul 2025.
- 14 Nov 2023 Planned End Date changed from 2 Nov 2023 to 2 Nov 2024.